Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKLR | P30613 | 2/20 | 1.00 |
| ▸ | PDE2A | O00408 | 1/20 | 0.79 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.69 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | HSD17B3 | P37058 | 3/20 | 0.61 |
| ▸ | ESR1 | P03372 | 4/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | GLA | P06280 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | MAOA | P21397 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29369342 | 1.00 | PKLR (1.00) | PKLRPDE2ANPSR1RXFP1MAPT | |
| SCHEMBL14294225 | 0.93 | PKLR (0.87) | PKLRPDE2ANPSR1RXFP1MAPT | |
| SCHEMBL16663940 | 0.89 | PDE2A (0.85) | PKLRPDE2ANPSR1RXFP1MAPT | |
| SCHEMBL803408 | 0.89 | PDE2A (1.00) | PKLRPDE2ANPSR1RXFP1MAPT | |
| SCHEMBL29368885 | 0.89 | PDE2A (1.00) | PKLRPDE2ANPSR1RXFP1MAPT | |
| SCHEMBL29401099 | 0.89 | PDE2A (1.00) | PKLRPDE2ANPSR1RXFP1MAPT | |
| SCHEMBL26772728 | 0.89 | PKLR (0.79) | PKLRPDE2ANPSR1RXFP1MAPT | |
| SCHEMBL26772481 | 0.89 | PKLR (0.79) | PKLRPDE2ANPSR1RXFP1MAPT | |
| SCHEMBL26772733 | 0.89 | PKLR (0.79) | PKLRPDE2ANPSR1RXFP1MAPT | |
| SCHEMBL26768208 | 0.89 | PKLR (0.79) | PKLRPDE2ANPSR1RXFP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119331299-A | Multi-monomer alternaria alternata molecular engram polymer, preparation method and application thereof | 新疆新康农业发展有限公司 | 2025-01-21 | — | — | CN | claimed |
| CN-114760996-A | Direct AMPK activator compounds in combination with indirect AMPK activator compounds, compositions, methods, and uses thereof | 雀巢产品有限公司 | 2022-07-15 | — | — | CN | claimed |
| EP-4555997-A1 | WATER-SOLUBLE COMPOSITION COMPRISING UROLITHIN | Science4Beauty Sp. z o.o. (PL) | 2025-05-21 | — | — | EP | disclosed |
| WO-2025078645-A1 | COSMETIC USE OF AT LEAST UROLITHIN B OR C ON A SENSITIVE SKIN | L'OREAL (FR) | 2025-04-17 | — | — | WO | disclosed |
| CN-116440874-B | Cross-linked spore phenol adsorbent based on aptamer functionalized magnetic hydrophobic polymer and application thereof | 北京市农林科学院 | 2025-02-18 | — | — | CN | disclosed |
| CN-119331299-A | Multi-monomer alternaria alternata molecular engram polymer, preparation method and application thereof | 新疆新康农业发展有限公司 | 2025-01-21 | — | — | CN | disclosed |
| US-12115178-B2 | Acylated active agents and methods of their use for the treatment of autoimmune disorders | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2024-10-15 | — | — | US | disclosed |
| EP-3634430-B1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2024-08-07 | — | — | EP | disclosed |
| US-20240180941-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2024-06-06 | — | — | US | disclosed |
| US-11820751-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2023-11-21 | — | — | US | disclosed |
| US-11813272-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20170143667-A1 | Compositions and Methods for Improving Mitochondrial Function and Treating Neurodegenerative Diseases and Cognitive Disorders | AMAZENTIS SA (CH) | 2017-05-25 | — | — | US | disclosed |
| US-20170143666-A1 | COMPOSITIONS AND METHODS FOR IMPROVING MITOCHONDRIAL FUNCTION AND TREATING NEURODEGENERATIVE DISEASES AND COGNITIVE DISORDERS | AMAZENTIS SA (CH) | 2017-05-25 | — | — | US | disclosed |
| US-20160000753-A1 | Enhancing Autophagy or Increasing Longevity by Administration of Urolithins or Precursors Thereof | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2016-01-07 | — | — | US | disclosed |
| US-20160000753-A1 | Enhancing Autophagy or Increasing Longevity by Administration of Urolithins or Precursors Thereof | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2016-01-07 | — | — | US | disclosed |
| US-20150336981-A1 | MODIFIED POLYPHENOLS AND MODIFIED POLYPHENOL COMPOSITIONS | CELLAROUGE PTY LTD (AU) | 2015-11-26 | — | — | US | disclosed |
| US-20150336981-A1 | MODIFIED POLYPHENOLS AND MODIFIED POLYPHENOL COMPOSITIONS | CELLAROUGE PTY LTD (AU) | 2015-11-26 | — | — | US | disclosed |
| EP-2862568-A1 | Compositions comprising urolithins and uses thereof for the stimulation of insulin secretion | Centre National de la Recherche Scientifique (CNRS) (FR) | 2015-04-22 | — | — | EP | disclosed |
| US-20140018415-A1 | Enhancing Autophagy or Increasing Longevity by Administration of Urolithins or Precursors Thereof | AMAZENTIS SA (CH) | 2014-01-16 | — | — | US | disclosed |
| US-20140018415-A1 | Enhancing Autophagy or Increasing Longevity by Administration of Urolithins or Precursors Thereof | AMAZENTIS SA (CH) | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170143666-A1 | COMPOSITIONS AND METHODS FOR IMPROVING MITOCHONDRIAL FUNCTION AND TREATING NEURODEGENERATIVE DISEASES AND COGNITIVE DISORDERS | NLN, TUFM, TFAM | PKLR 2330/4885PDE2A 1188/4885NPSR1 3719/4885 |
| US-11813272-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FABP1, PYGL, LIPC | PKLR 1133/4885PDE2A 1685/4885NPSR1 1420/4885 |
| US-20240180941-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FABP1, PYGL, LIPC | PKLR 1133/4885PDE2A 1685/4885NPSR1 1420/4885 |
| US-20170143667-A1 | Compositions and Methods for Improving Mitochondrial Function and Treating Neurodegenerative Diseases and Cognitive Disorders | NLN, TUFM, TFAM | PKLR 1697/4885PDE2A 1530/4885NPSR1 3498/4885 |
| US-20160000753-A1 | Enhancing Autophagy or Increasing Longevity by Administration of Urolithins or Precursors Thereof | ATG7, BECN1, ATG4A | PKLR 2385/4885PDE2A 2192/4885NPSR1 4301/4885 |
| US-20150336981-A1 | MODIFIED POLYPHENOLS AND MODIFIED POLYPHENOL COMPOSITIONS | PGC, COMT, EGLN2 | PKLR 1239/4885PDE2A 2731/4885NPSR1 4119/4885 |
| US-12115178-B2 | Acylated active agents and methods of their use for the treatment of autoimmune disorders | ENPP2, MBOAT7, AADAC | PKLR 4246/4885PDE2A 1312/4885NPSR1 3210/4885 |
| US-20140018415-A1 | Enhancing Autophagy or Increasing Longevity by Administration of Urolithins or Precursors Thereof | ATG7, BECN1, ATG4A | PKLR 2385/4885PDE2A 2192/4885NPSR1 4301/4885 |
| US-11820751-B2 | Urolithin derivatives and methods of use thereof | NLN, UQCRC2, TUFM | PKLR 1783/4885PDE2A 1089/4885NPSR1 3213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.